您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Propranolol D7 hydrochloride
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Propranolol D7 hydrochloride
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Propranolol D7 hydrochloride图片
CAS NO:1613439-56-7
包装与价格:
包装价格(元)
1mg电议
5mg电议

产品介绍
PropranololD7hydrochloride是Propranololhydrochloride的氘代物。Propranololhydrochloride是一种非选择性的β-adrenergicreceptor(βAR)拮抗剂,对β1AR和β2AR具有高亲和力,Ki值分别为1.8nM和0.8nM。Propranololhydrochloride抑制[3H]-DHA与大鼠脑膜制剂的结合,IC50为12nM。Propranololhydrochloride用于高血压,嗜铬细胞瘤,心肌梗塞,心律不齐,心绞痛和肥大心肌病的相关研究。
Cas No.1613439-56-7
别名盐酸普萘洛尔 d7 (盐酸盐)
Canonical SMILESOC(COC1=C2C=CC=CC2=CC=C1)CNC(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H].[H]Cl
分子式C16H15D7ClNO2
分子量302.85
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Propranolol D7 hydrochloride is a deuterium labeled Propranolol hydrochloride. Propranolol hydrochloride is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively[1]. Propranolol hydrochloride inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM[2]. Propranolol hydrochloride is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy[3].

[1]. Galandrin S, et al. Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol. 2006 Nov;70(5):1575-84. [2]. Briley M, et al. Evidence against beta-adrenoceptor blocking activity of diltiazem, a drug with calcium antagonist properties. Br J Pharmacol. 1980 Aug;69(4):669-73. [3]. Al-Majed AA, et al. Propranolol. Profiles Drug Subst Excip Relat Methodol. 2017;42:287-338.